JP2013241466A5 - - Google Patents

Download PDF

Info

Publication number
JP2013241466A5
JP2013241466A5 JP2013174418A JP2013174418A JP2013241466A5 JP 2013241466 A5 JP2013241466 A5 JP 2013241466A5 JP 2013174418 A JP2013174418 A JP 2013174418A JP 2013174418 A JP2013174418 A JP 2013174418A JP 2013241466 A5 JP2013241466 A5 JP 2013241466A5
Authority
JP
Japan
Prior art keywords
gal
preparation
subject
dose
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013174418A
Other languages
English (en)
Japanese (ja)
Other versions
JP5899169B2 (ja
JP2013241466A (ja
Filing date
Publication date
Priority claimed from US09/266,014 external-priority patent/US6458574B1/en
Application filed filed Critical
Publication of JP2013241466A publication Critical patent/JP2013241466A/ja
Publication of JP2013241466A5 publication Critical patent/JP2013241466A5/ja
Application granted granted Critical
Publication of JP5899169B2 publication Critical patent/JP5899169B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2013174418A 1999-03-11 2013-08-26 α−ガラクトシダーゼＡ欠乏症の治療 Expired - Lifetime JP5899169B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/266,014 US6458574B1 (en) 1996-09-12 1999-03-11 Treatment of a α-galactosidase a deficiency
US09/266,014 1999-03-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010215000A Division JP5615648B2 (ja) 1999-03-11 2010-09-27 α−ガラクトシダーゼＡ欠乏症の治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014254079A Division JP6081980B2 (ja) 1999-03-11 2014-12-16 α−ガラクトシダーゼＡ欠乏症の治療

Publications (3)

Publication Number Publication Date
JP2013241466A JP2013241466A (ja) 2013-12-05
JP2013241466A5 true JP2013241466A5 (https=) 2014-10-16
JP5899169B2 JP5899169B2 (ja) 2016-04-06

Family

ID=23012821

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2000603353A Pending JP2002538183A (ja) 1999-03-11 2000-03-09 α−ガラクトシダーゼＡ欠乏症の治療
JP2010215000A Expired - Lifetime JP5615648B2 (ja) 1999-03-11 2010-09-27 α−ガラクトシダーゼＡ欠乏症の治療
JP2013174418A Expired - Lifetime JP5899169B2 (ja) 1999-03-11 2013-08-26 α−ガラクトシダーゼＡ欠乏症の治療
JP2014254079A Expired - Lifetime JP6081980B2 (ja) 1999-03-11 2014-12-16 α−ガラクトシダーゼＡ欠乏症の治療
JP2016200833A Expired - Lifetime JP6346236B2 (ja) 1999-03-11 2016-10-12 α−ガラクトシダーゼＡ欠乏症の治療
JP2017219734A Expired - Lifetime JP6626071B2 (ja) 1999-03-11 2017-11-15 α−ガラクトシダーゼＡ欠乏症の治療

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000603353A Pending JP2002538183A (ja) 1999-03-11 2000-03-09 α−ガラクトシダーゼＡ欠乏症の治療
JP2010215000A Expired - Lifetime JP5615648B2 (ja) 1999-03-11 2010-09-27 α−ガラクトシダーゼＡ欠乏症の治療

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014254079A Expired - Lifetime JP6081980B2 (ja) 1999-03-11 2014-12-16 α−ガラクトシダーゼＡ欠乏症の治療
JP2016200833A Expired - Lifetime JP6346236B2 (ja) 1999-03-11 2016-10-12 α−ガラクトシダーゼＡ欠乏症の治療
JP2017219734A Expired - Lifetime JP6626071B2 (ja) 1999-03-11 2017-11-15 α−ガラクトシダーゼＡ欠乏症の治療

Country Status (22)

Country Link
US (4) US6458574B1 (https=)
EP (6) EP1163349B1 (https=)
JP (6) JP2002538183A (https=)
KR (2) KR100961740B1 (https=)
CN (4) CN103585621B (https=)
AT (1) ATE386808T1 (https=)
AU (1) AU3519400A (https=)
CA (3) CA3012663A1 (https=)
CY (3) CY1107951T1 (https=)
DE (1) DE60038104T2 (https=)
DK (3) DK2314699T3 (https=)
ES (3) ES2300256T3 (https=)
HK (2) HK1043386B (https=)
HU (1) HU228743B1 (https=)
IL (2) IL145381A0 (https=)
MX (1) MXPA01009222A (https=)
NO (2) NO329689B1 (https=)
NZ (1) NZ514077A (https=)
PL (1) PL210833B1 (https=)
PT (3) PT1163349E (https=)
RU (1) RU2248213C2 (https=)
WO (1) WO2000053730A2 (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
IL155588A0 (en) * 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) * 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
EP1503788B1 (en) * 2002-04-25 2011-06-29 Shire Human Genetic Therapies, Inc. Treatment of alpha-galactosidase a deficiency
PT2441467E (pt) 2003-01-31 2015-10-12 Sinai School Medicine Terapia combinada para o tratamento de transtornos associados a uma deficiência proteica
US7422310B2 (en) * 2003-04-25 2008-09-09 Hewlett-Packard Development Company, L.P. Methods and apparatus for selecting image enhancement techniques
US20100196345A1 (en) * 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
US7442372B2 (en) † 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CN1922313B (zh) 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
JP2008503590A (ja) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド 組成物を細胞にデリバリーするための医学用システム及び方法
CN1308444C (zh) * 2005-04-15 2007-04-04 中国人民解放军军事医学科学院野战输血研究所 基因重组α－半乳糖苷酶大批量发酵液的纯化方法
EP2932982B1 (en) 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
BRPI0618583A2 (pt) * 2005-11-18 2011-09-06 Tokyo Metropolitan Org Med Res enzima altamente funcional tendo especifidade ao substrato modificada
WO2007086067A1 (en) * 2006-01-30 2007-08-02 Diagnostic Technologies Ltd. Method for monitoring tocolytic treatment
US20090117091A1 (en) * 2006-11-13 2009-05-07 Lebowitz Jonathan Methods for treating pompe disease
CN101861382B (zh) * 2007-05-07 2015-07-15 普罗塔里克斯有限公司 大规模一次性生物反应器
EP2185187A1 (en) * 2007-08-29 2010-05-19 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
HRP20170698T1 (hr) 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011107990A1 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2011133802A1 (en) * 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
CA2805557A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant high molecular weight vwf in cell culture
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
ES2746554T3 (es) 2010-11-02 2020-03-06 Univ Columbia Métodos para tratar los trastornos de pérdida de cabello
BR112013022277B1 (pt) 2011-03-04 2021-08-03 Glytech, Inc Método para produção de cadeia de açúcar contendo ácido siálico
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
KR20200032244A (ko) 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
EP3459565A1 (en) 2012-03-29 2019-03-27 The Trustees of Columbia University in the City of New York Methods for treating hair loss disorders
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
HK1209625A1 (en) * 2012-07-17 2016-04-08 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
WO2014016873A1 (en) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
JP6226435B2 (ja) * 2012-07-26 2017-11-08 Ｊｃｒファーマ株式会社 組換えヒトα−ガラクトシダーゼＡの製造方法
WO2014120900A1 (en) * 2013-01-31 2014-08-07 Icahn School Of Medicine At Mount Sinai Enhanced therapeutic regimens for treating fabry disease
DK2971098T3 (en) 2013-03-14 2019-02-18 Translate Bio Inc QUANTITATIVE ASSESSMENT FOR CAPE EFFECTIVENESS OF MESSENGER RNA
CN105051213A (zh) 2013-03-14 2015-11-11 夏尔人类遗传性治疗公司 信使rna加帽效率的定量评估
TW202332774A (zh) 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
PE20161417A1 (es) 2014-03-05 2017-01-22 Ultragenyx Pharmaceutical Inc Composiciones de glicoproteinas sialiladas y uso de estas
WO2016054231A1 (en) 2014-09-30 2016-04-07 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
KR20250025516A (ko) 2014-12-22 2025-02-21 젠자임 코포레이션 포유류 세포의 배양 방법
FI3237621T3 (fi) * 2014-12-22 2023-06-01 Codexis Inc Ihmisen alfa-galaktosidaasivariantteja
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
CA2997947A1 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
IL325155A (en) 2016-03-30 2026-02-01 Amicus Therapeutics Inc Formulations containing recombinant acid alpha-glucosidase
US10227577B2 (en) * 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
CA3039673A1 (en) * 2016-10-20 2018-04-26 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of fabry disease
TW201829770A (zh) 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
EA039750B1 (ru) * 2017-03-30 2022-03-10 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
WO2020047282A1 (en) * 2018-08-29 2020-03-05 University Of Copenhagen Lysosomal enzymes modified by cell based glycoengineering
SG11202106348QA (en) * 2018-12-20 2021-07-29 Codexis Inc Human alpha-galactosidase variants
EP3996696A1 (en) 2019-07-09 2022-05-18 Genethon Treatment of glycogen storage disease (gsd)
TW202128264A (zh) * 2019-09-25 2021-08-01 瑞士商赫孚孟拉羅股份公司 使用經預測之溶離緩衝鹽濃度的陽離子層析法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5322158B2 (https=) * 1974-05-02 1978-07-06
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
DE3580384D1 (de) 1984-04-09 1990-12-13 Toyo Boseki Praeparat mit verzoegerter freigabe zum aufbringen auf die schleimhaeute der mundhoehle.
US4764376A (en) 1984-06-18 1988-08-16 Eli Lilly And Company Method of inhibiting aromatase
GB8530631D0 (en) * 1985-12-12 1986-01-22 Ciba Geigy Ag Thrombin inhibitors
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5272066A (en) * 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5382518A (en) * 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
CA2041638C (en) * 1989-09-05 2001-05-15 Peter L. Whitfeld Recombinant polynucleotide constructs suitable for providing secretion of pai-2
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5858751A (en) 1992-03-09 1999-01-12 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
ES2179831T3 (es) 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
US5389539A (en) 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
EP0726964A4 (en) * 1993-09-23 1999-01-13 New England Biolabs Inc INSULATION AND COMPOSITION OF NEW GLYCOSIDASES
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5843015A (en) 1993-12-28 1998-12-01 Becton Dickinson And Company Molecules for iontophoretic delivery
US5789247A (en) 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
JPH10513057A (ja) * 1995-01-30 1998-12-15 ニューヨーク・ブラッド・センター・インコーポレイテッド 組換えα−ガラクトシダーゼ酵素
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
JP4001925B2 (ja) 1996-09-13 2007-10-31 トランスカーヨティック セラピーズ インク． α―ガラクトシダーゼＡ欠損症の治療
IL125423A (en) * 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes

Similar Documents

Publication Publication Date Title
JP2013241466A5 (https=)
US20230079225A1 (en) Method For Selection Of High M6P Recombinant Proteins
US20240066104A1 (en) Formulations comprising recombinant acid alpha-glucosidase
WO2012015692A2 (en) Recombinantly expressed insulin polypeptides and uses thereof
CN103889444A (zh) N-糖基化的胰岛素类似物
KR20250110931A (ko) 소아 환자의 영아-발병 폼페병 치료에 대한 방법
CN109475607B (zh) 包含重组酸性α-葡糖苷酶的配制品
US11192874B2 (en) Use of pharmacological chaperones for the treatment of lysosomal storage diseases
HK40076131A (en) Formulations comprising recombinant acid alpha-glucosidase
HK1262140B (en) Formulations comprising recombinant acid alpha-glucosidase
HK1259321A1 (zh) 用於选择高m6p重组蛋白的方法
HK1259321B (zh) 用於选择高m6p重组蛋白的方法
BR112018070189B1 (pt) Método para seleção de proteínas recombinantes ricas em m6p